Inflammatory Bowel Disease (IBD) is a disorder of the gastrointestinal tract,
which is characterized by Crohn’s disease and Ulcerative colitis. Ulcerative colitis (UC) is
a chronic idiopathic relapsing colon disease distinguishes by the interference of epithelial
wall and colonic site tenderness. For the treatment of ulcerative colitis, various side effects
have been reported, due to the non-specific delivery of the targeted drug of the conventional
system. This review will explain the reader about various considerations for the preparation
of orally administered NPs drug delivery systems for the treatment of ulcerative colitis.
Moreover, principles and novel strategies for colon targeting based on the physiology
of colon so that the tract of gastro intestine can be used as the identification marker for a
target site for drugs. Besides this, the role of phytomedicines in controlling and managing
the ulcerative colitis has been discussed. Additionally, the major problem for the smart delivery
of NPs in clinical applications with their difficulties in Intellectual Property Rights
(IPR) was also discussed. Finally, this review provides various potential approaches to NPs
for the treatment of UC.
Keywords: Colon targeted drug delivery, identification markers, nanoparticles, ulcerative colitis, Inflammatory
Bowel Disease (IBD), Crohn’s disease.
Rights & PermissionsPrintExport